Section 32 β 2022 Investments
4 investments dated 2022 Β· listed companies and verified rows first Β· show all
Big Hat Bio develops therapeutics under development across multiple programs.
AI & Machine LearningBiotechDeep TechSan Francisco, US
Peyton Greenside(Executive Officer, Director)inMark DePristo(Executive Officer, Director)in
BoardFrancisco Gimenez(Director)inSteve Kafka(Director)Vineeta Agarwala(Director)inRobert Chess(Director)
Co-investors8VCAndreessen HorowitzBOLD LongevityFlucas VenturesGRIDS CapitalAME Cloud Ventures+5 more
A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.
Biotech
Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in
Co-investorsNextech InvestThird Rock VenturesAlexandriaCasdin CapitalCreacion VenturesGoldman Sachs+3 more
Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.
AI & Machine LearningBiotechHealthtech
Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)inDarrin Miles(Chief Executive Officer)inPhilip Komarnitsky(Chief Medical Officer)inTanja Weber(Chief Business Officer)in
Co-investorsVersant VenturesForesite CapitalSixty Degree CapitalCowen Healthcare InvestmentsGoldman Sachs
ONI develops the Nanoimager, an automated super-resolution imaging system.
BiotechDeep TechHardwareMedical DevicesOxford, GB
Co-investorsARCH Venture PartnersArtis VenturesFuture Planet CapitalOxford Technology ManagementVertical Venture PartnersAxon Ventures+3 more
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.